Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Researchers conducted a meta-analysis of studies to explore the efficacy and safety of pembrolizumab alone and in combination with chemotherapy for the treatment of gastric and GEJ cancers.

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

Pembrolizumab (Keytruda, Merck) is an anti-PD-1 therapy. Healio previously reported that the FDA approved this combination for the treatment of certain women with stage III to stage IVA cervical ...

Findings showed sacituzumab govitecan-hziy + pembrolizumab significantly improved ... cancer in patients who have received endocrine-based therapy and at least 2 additional systemic therapies ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Adagrasib and pembrolizumab combination therapy achieved a median PFS of 27.7 months in KRASG12C-mutated NSCLC patients with PD-L1 ≥50%. The combination therapy showed a 59.3% overall response ...

Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.